• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型口服活性多巴胺前药N-(N-乙酰-L-甲硫氨酰)-O,O-双(乙氧羰基)多巴胺(TA-870)及多巴胺在大鼠和犬口服给药后的代谢

Metabolism of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine (TA-870) and dopamine after oral administration to rats and dogs.

作者信息

Yoshikawa M, Endo H, Komatsu K, Sugawara Y, Takaiti O

机构信息

Biological Research Laboratory, Tanabe Seiyaku Co., Ltd., Saitama, Japan.

出版信息

J Pharmacobiodyn. 1990 Apr;13(4):246-53. doi: 10.1248/bpb1978.13.246.

DOI:10.1248/bpb1978.13.246
PMID:2384858
Abstract

The metabolism of an orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine (TA-870) and of dopamine (DA), were studied by use of thin layer chromatography (TLC) and high performance liquid chromatography (HPLC) for identification and analysis of urinary and biliary metabolites after p.o. and/or i.v. administration to rats and dogs. The conjugated/free ratios of the metabolites were also determined. The urinary metabolites and order of the excretion in rats after p.o. dosing of TA-870 (30 mg/kg) were DA greater than homovanillic acid (HVA) greater than 3,4-dihydroxyphenylacetic acid (DOPAC) greater than 3-hydroxyphenylacetic acid (3-HPAC). Those in dogs (33.5 mg/kg p.o.) were DA greater than HVA greater than de-ethoxycarbonylated TA-870 (DEC-TA-870) not equal to DOPAC. The urinary metabolites and order of the excretion in rats after p.o. dosing of DA (12 mg/kg, equimolar dose to TA-870) were DA greater than DOPAC greater than HVA greater than 3-HPAC, while those in dogs (13.5 mg/kg) were DOPAC greater than DA greater than HVA. The composition of the main urinary metabolites of TA-870 are similar in rats and dogs but after p.o. dosing of DA, excretion of DOPAC in dogs is much (ca. 3 times) higher than that in rats. After administration of DA and TA-870, 3-HPAC was found as a novel metabolite of DA, which was thought to be formed by dehydroxylation of DOPAC or DA with intestinal flora.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

通过薄层色谱法(TLC)和高效液相色谱法(HPLC)研究了口服活性多巴胺前药N-(N-乙酰-L-甲硫氨酰)-O,O-双(乙氧羰基)多巴胺(TA-870)和多巴胺(DA)的代谢情况,以鉴定和分析大鼠和犬经口和/或静脉给药后尿液和胆汁中的代谢产物。还测定了代谢产物的结合型/游离型比率。大鼠经口给予TA-870(30mg/kg)后,尿液中的代谢产物及其排泄顺序为:多巴胺>高香草酸(HVA)>3,4-二羟基苯乙酸(DOPAC)>3-羟基苯乙酸(3-HPAC)。犬经口给予(33.5mg/kg)后为:多巴胺>高香草酸>脱乙氧羰基化TA-870(DEC-TA-870)≠3,4-二羟基苯乙酸。大鼠经口给予多巴胺(12mg/kg,与TA-870等摩尔剂量)后,尿液中的代谢产物及其排泄顺序为:多巴胺>3,4-二羟基苯乙酸>高香草酸>3-羟基苯乙酸,而犬经口给予(13.5mg/kg)后为:3,4-二羟基苯乙酸>多巴胺>高香草酸。TA-870主要尿液代谢产物的组成在大鼠和犬中相似,但经口给予多巴胺后,犬中3,4-二羟基苯乙酸的排泄量比大鼠高得多(约3倍)。给予多巴胺和TA-870后,发现3-羟基苯乙酸是多巴胺的一种新代谢产物,推测它是由3,4-二羟基苯乙酸或多巴胺经肠道菌群脱羟基形成的。(摘要截短于250字)

相似文献

1
Metabolism of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine (TA-870) and dopamine after oral administration to rats and dogs.新型口服活性多巴胺前药N-(N-乙酰-L-甲硫氨酰)-O,O-双(乙氧羰基)多巴胺(TA-870)及多巴胺在大鼠和犬口服给药后的代谢
J Pharmacobiodyn. 1990 Apr;13(4):246-53. doi: 10.1248/bpb1978.13.246.
2
First pass metabolism and in vitro metabolism of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine in dogs.新型口服活性多巴胺前药N-(N-乙酰基-L-甲硫氨酰基)-O,O-双(乙氧羰基)多巴胺在犬体内的首过代谢及体外代谢
Drug Metab Dispos. 1991 Sep-Oct;19(5):960-5.
3
Disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl) dopamine (TA-870) in humans.
Drug Metab Dispos. 1990 Mar-Apr;18(2):212-7.
4
A novel orally active dopamine prodrug TA-870. I. Renal and cardiovascular effects and plasma levels of free dopamine in dogs and rats.一种新型口服活性多巴胺前药TA - 870。I. 对犬和大鼠的肾脏、心血管作用及游离多巴胺的血浆水平
J Cardiovasc Pharmacol. 1989 Jun;13(6):879-86. doi: 10.1097/00005344-198906000-00010.
5
Comparative study on the disposition of a new orally active dopamine prodrug, N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)dopamine (TA-870) and dopamine hydrochloride in rats and dogs.新型口服活性多巴胺前药N-(N-乙酰-L-甲硫氨酰)-O,O-双(乙氧羰基)多巴胺(TA-870)与盐酸多巴胺在大鼠和犬体内处置的比较研究。
Drug Metab Dispos. 1988 Sep-Oct;16(5):754-8.
6
A novel orally active dopamine prodrug TA-870. II. Evidence that TA-870 is a dopamine prodrug.一种新型口服活性多巴胺前药TA-870。II. TA-870是多巴胺前药的证据。
J Cardiovasc Pharmacol. 1989 Aug;14(2):175-83. doi: 10.1097/00005344-198908000-00001.
7
Bioavailability and pharmacokinetics of an oral dopamine prodrug in dogs.一种口服多巴胺前体药物在犬体内的生物利用度和药代动力学
J Pharm Sci. 1989 Oct;78(10):812-4. doi: 10.1002/jps.2600781006.
8
Pharmacokinetic analysis of absorption and metabolism of dopamine and a dopamine prodrug in dogs.多巴胺及一种多巴胺前药在犬体内吸收与代谢的药代动力学分析。
Biopharm Drug Dispos. 1990 Mar;11(2):149-56. doi: 10.1002/bdd.2510110207.
9
Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease.慢性肾实质疾病中多巴胺及其代谢产物的尿排泄减少。
Kidney Blood Press Res. 1998;21(1):59-65. doi: 10.1159/000025844.
10
Assessment of renal dopaminergic system activity during cyclosporine A administration in the rat.环孢素A给药期间大鼠肾脏多巴胺能系统活性的评估。
Br J Pharmacol. 1995 Aug;115(8):1349-58. doi: 10.1111/j.1476-5381.1995.tb16623.x.